Hepatic disease drug developer Conatus nets $61.4mm in initial public offering
Executive Summary
Conatus Pharmaceuticals Inc. (focused on hepatic diseases) has netted $61.4mm in its initial public offering. The company sold 6mm shares--1mm more than planned--at $11, the mid-point of its $10-12 price range.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice